ESTRO 2020 Abstract book

S1129 ESTRO 2020

At first sign of faint/dull erythema (RTOG 1) each patient changed their skincare product to Flamigel®RT and advised to use it three times a day. Post Radiotherapy a specifically designed evaluation form was completed for each patient. The evaluation forms were reviewed and each question statistically analysed. Results During radiotherapy 98.25% only developed faint/dull erythema (RTOG 1). 97.4% of the patients found Flamigel®RT to be soothing upon application. 85% of patients found that Flamigel®RT improved pruritus. At the two-week post radiotherapy follow up review 28.85% had no skin reaction (RTOG 0), 50% had faint/dull erythema (RTOG 1), 17.31% had bright erythema (RTOG 2a) and 3.85% developed patchy moist desquamation (RTOG 2b). 98.41% of the patients would recommend using Flamigel®RT. Conclusion This evaluation showed that using Flamigel RT can improve the skin reaction not only reducing the incidences of moist desquamation for patients having breast radiotherapy, but also soothes the patient’s skin and reduces itchiness. Due to the positive feedback from the patients, a new skincare protocol using Flamigel®RT was designed and adopted across our centres to enhance patient care experience. PO-1932 Patients-Reported Outcomes (PROs) following SBRT for clinically localized Prostate Cancer A. Mańczak 1 , P. Milecki 1 1 Greater Poland Cancer Center, Radiotherapy Department I, Poznań, Poland Purpose or Objective Aim of the study is to assessment of influence of treatment with SBRT on the PROs in patients with localized prostate cancer. Material and Methods Between July 2013 and May 2014 95 patients with clinically localized prostate cancer were irradiated with SBRT using the CyberKnife platform at the Radiotherapy Department in Greater Poland Cancer Center. SBRT was delivered with daily fraction dose of 7.0 Gy or 7.25 Gy, administered every other day, to total dose of 35.0 Gy or 36.25 Gy. For all patients the evaluation of PROs were based on the International Prostate Score Symptoms (IPSS) and the EORTC Quality of Life questionnaire PR-25 module (Prostate module), completed at baseline (pre- treatment), at the end of therapy, 1 and 24 months from the completion of the RT. Results For all patients at the end of therapy and one month after completion of SBRT summary scores for IPSS and PR 25 module decreased in comparison to baseline level. Based on the results, all patients had a worsening of the urinary tract symptoms during early period of follow-up but at 24 months after RT level of IPSS and EORTC module PR 25 scores were compared with the pre-treatment outcome. Conclusion The results of our study confirm good tolerance of ultrahypofractionated SBRT prostate cancer and suggests that SBRT due to short treatment time, equally high efficacy and good tolerance, could in the future replace conventional fractionated radiotherapy in treatment of prostate cancer.

Purpose or Objective Clinical trials improve health care by testing new medications and treatments as well as steering treatment guidelines. Conclusions from these trials can only be drawn when there is enough statistical power, for which, large numbers of patients are needed. Unfortunately, still a significant number of patients decline to participate for a variety of reasons, such as being overwhelmed by fear of their cancer and misconceptions due to insufficient knowledge about clinical trials. Decision aids help reduce patients’ decisional conflict, increase their knowledge, and increase their perceived level of involvement. Previously we developed a web- based patient decision aid for trial participation (tDAT) to increase participation rates by better informing patients about clinical trials. The aim of this study is to assess factors influencing patients’ willingness to participate in clinical trials in order to develop a baseline measurement of the current information provision at our clinic. Material and Methods We conducted a retrospective study using the general patient satisfaction survey (CQI), sent to all patients treated at our clinic between 2016-2019, as well as notes made by the trial outpatient nurse. As a benchmark, survey data was compared with existing literature. Known confounders were used to discriminate between results, e.g. age, gender, education status, type of cancer. Results The overall response rate to the CQI survey was 65%. 95% of these patients received information on participation in a clinical trial at our clinic, of which two-thirds decided to participate in a clinical trial. Preliminary results showed that patients cited multiple factors influencing decisions to participate in clinical trials, the most important reason being that the trial result could benefit others. Additionally, we expect that the mutual cohesion between security of the patient, lack of knowledge of clinical trials, the relationship between patient and informed consent person and the method of giving information have influence on the decision to participate or not. Conclusion We conclude that altruism is a major factor for patients to participate in clinical trials. To increase patient participation in clinical trials, we will test our hypothesis that the tDAT increases knowledge and therefore likelihood to participate in a trial In the near future, we will be conducting a trial to evaluate the effect of implementing the tDAT. PO-1931 To evaluate Flamigel®RT in the skincare pathway for patients having breast radiotherapy. J. Rigley 1 , G. Grant 2 , T. Alagbe 3 1 Genesis Care Nottingham, Radiotherapy, Nottingham, United Kingdom ; 2 Genesis Care, Elstree, London, United Kingdom ; 3 Genesis Care, Milton Keynes, Milton Keynes, United Kingdom Purpose or Objective Erythema is a common side effect of breast Radiotherapy and can often develop into moist desquamation. The aim of this evaluation was to gain evidence in the effectiveness of Flamigel®RT in reducing incidences of moist desquamation and whether our skincare pathway can be adapted to improve the patient care experience in our centres. Material and Methods 64 patients having radiotherapy to the breast or chest wall were included in this evaluation. From day one of radiotherapy each patient used their chosen moisturiser either E45 cream, Aveeno or Aloe Vera gel.